This brand name is authorized in Estonia, Lithuania.
The drug NUMIENT contains a combination of these active pharmaceutical ingredients (APIs):
1
|
UNII
46627O600J - LEVODOPA
|
|
Levodopa is a precursor of dopamine, and is given as dopamine replacement therapy in Parkinson's disease. |
|
2
|
UNII
MNX7R8C5VO - CARBIDOPA
|
|
Carbidopa is a peripheral aromatic amino acid decarboxylase inhibitor. It prevents metabolism of levodopa to dopamine in the peripheral circulation, ensuring that a higher proportion of the dose reaches the brain, where dopamine exerts its therapeutic effects. A lower dose of levodopa can be used when it is coadministered with carbidopa, reducing the incidence and severity of peripheral side effects. |
|
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| N04BA02 | Levodopa and decarboxylase inhibitor | N Nervous system → N04 Anti-parkinson drugs → N04B Dopaminergic agents → N04BA Dopa and dopa derivatives |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| EE | Ravimiamet | 1704945, 1704956, 1704967, 1704978, 1704989, 1704990, 1705003, 1705014, 1705025, 1705036, 1705047, 1705058 |
| LT | Valstybinė vaistų kontrolės tarnyba | 1079098, 1079099, 1079100, 1079101, 1079102, 1079103, 1079104, 1079105, 1079106, 1079107, 1079108, 1079109 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.